Results 41 to 50 of about 2,131 (185)

The Anti-CGRP Antibody Fremanezumab Lowers CGRP Release from Rat Dura Mater and Meningeal Blood Flow

Cells, 2022
Monoclonal antibodies directed against the neuropeptide calcitonin gene-related peptide (CGRP) belong to a new generation of therapeutics that are effective in the prevention of migraine.
Mária Dux, Birgit Vogler, Annette Kuhn, Kimberly D. Mackenzie, Jennifer Stratton, Karl Messlinger   +5 more
doaj   +1 more source

PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine: infographic

, 2022
Infographic. PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic ...
Leonidas Lyras (11907976), Cristina Tassorelli (665097), Dimos-Dimitrios Mitsikostas (5196293), Joshua M. Cohen (9346644), Martijn Konings (11907974), Faisal Mohammad Amin (9039018), Pinar Kokturk (11907972), Messoud Ashina (740642)   +7 more
core   +1 more source

Fremanezumab for Episodic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials

Journal of Pain Research, 2023
Kazumasa Saigoh,1 Takao Takeshima,2 Masami Nakai,3 Yoshiyuki Shibasaki,4 Miki Ishida,5 Xiaoping Ning,6 Steve Barash,6 Yuki Isogai,4 Nobuyuki Koga7 1Department of Neurology, Kindai University School of Medicine, Osaka, Japan; 2Headache Center, Department ...
Saigoh K, Takeshima T, Nakai M, Shibasaki Y, Ishida M, Ning X, Barash S, Isogai Y, Koga N   +8 more
doaj  

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Long-term treatment over 52 weeks with monthly fremanezumab in drug-resistant migraine. A prospective multicenter cohort study [PDF]

, 2023
Background: Real-world studies on fremanezumab, an anti-calcitonin gene-related peptide monoclonal antibody for migraine prevention, are few and with limited follow-up.
Chiarugi, Alberto, Sances, Grazia, Merlo, Paola, Sepe, Federica Nicoletta, null, null, Granato, Antonio, Sacco, Simona, Castro, Flavia Lo, Mampreso, Edoardo, Guerzoni, Simona, Iannone, Luigi Francesco, Gentile, Martino, Burgalassi, Andrea, Geppetti, Pierangelo, Battistini, Stefania, Casalena, Alfonsina, Fallacara, Adriana, Rainero, Innocenzo, Coppola, Gianluca, Silvestro, Marcello, Tessitore, Alessandro, Tassorelli, Cristina, De Cesaris, Francesco, Dalla Volta, Giorgio, Allena, Marta, Tabasso, Giorgio, Caponnetto, Valeria, De Tommaso, Marina, Garascia, Gabriele, Brovia, Daria, Vigani, Giulia, Beretta, Natascia, Rebecchi, Valentina, Manganotti, Paolo, Baraldi, Carlo, Baiata, Claudio, Ornello, Raffaele, Vaghi, Gloria, Russo, Antonio, De Icco, Roberto, Liaci, Giorgio, Prudenzano, Maria Pia, Onofri, Agnese, La Porta, Anna, Tronci, Stefano   +44 more
core   +1 more source

Novel targets in headache: A narrative review

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background This narrative review summarizes novel applications for the use of calcitonin gene‐related peptide (CGRP)‐targeted therapies that go beyond migraine, the latest updates with respect to targeting pituitary adenylate cyclase‐activating peptide (PACAP) as therapeutic in migraine, as well as exploring other more recently ...
Adriana Della Pietra, Peter J. Goadsby, Carolina Oldoni, Stephen Silberstein, Fred Cohen, Simon Akerman   +5 more
wiley   +1 more source

Distribution and target engagement of peripherally administered fremanezumab in the cerebrospinal fluid of healthy volunteers

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background Our objective was to describe the distribution of fremanezumab to the cerebrospinal fluid (CSF) in healthy volunteers, and investigate its engagement and stabilization of its target, calcitonin gene‐related peptide (CGRP). Fremanezumab is a CGRP‐targeting monoclonal antibody approved for migraine prevention.
Jacki Rorabaugh, Edward Hellriegel, Juline Bryson, Ryan Tiver, Hang Zeng, Xiaofeng Lu, Steve Barash, Giulia Ghibellini, Olga Szilagyi, Ignacio Echenique, Andrew H. Ahn, Peter J. Goadsby, Laura Rabinovich‐Guilatt   +12 more
wiley   +1 more source

Development of a machine learning (ML) model to predict 3‐month response to CGRP monoclonal antibodies in migraine: A pilot evaluation of physician‐ML model interaction

Headache: The Journal of Head and Face Pain, EarlyView.
Plain Language Summary Monoclonal antibodies that target calcitonin gene‐related peptide (CGRP‐mAbs) are effective treatments for preventing migraine in many patients but are expensive, and physicians cannot easily predict which patients will benefit from them.
Masahito Katsuki, Muneto Tatsumoto, Tomokazu Shimazu, Yasuhiko Matsumori, Marina Romozzi, Omid Kohandel Gargari, Alicia Gonzalez‐Martinez, Woo‐Seok Ha, Yutaro Fuse, Shiho Suzuki, Saro Kobayashi, Tomohiko Shiina, Mukuto Shioda, Hiroaki Fujita, Koichi Hirata, Yuya Kano, Ryosuke Fukazawa, Jackson T. S. Cheung, Siobhán O'Connor, Tomás Ward, Kieran Moran, Keisuke Suzuki   +21 more
wiley   +1 more source

Correction to: Fremanezumab: First Global Approval [PDF]

Drugs, 2019
The original article can be found online.
openaire   +2 more sources

Pregnancy outcomes following exposure to galcanezumab: Analysis of cases from the galcanezumab clinical trials and postmarketing database

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective This study was conducted to describe pregnancy outcomes reported following maternal or paternal exposure to galcanezumab in clinical trials and postmarketing surveillance. Background Galcanezumab is a calcitonin gene‐related peptide‐inhibiting monoclonal antibody indicated for the preventive treatment of migraine.
Irene Boz, Jan Lewis Brandes, Christopher Robinson, Maria Fernanda Scantamburlo Fernandes, Sarah Lipsius, LaRonda Morford, Enemona Emmanuel Adaji, Anaclara Prada Jardim, Holland C. Detke   +8 more
wiley   +1 more source